PH12017501248A1 - New association between 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione and an antidepresant and pharmaceutical compositions containing it - Google Patents

New association between 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione and an antidepresant and pharmaceutical compositions containing it

Info

Publication number
PH12017501248A1
PH12017501248A1 PH12017501248A PH12017501248A PH12017501248A1 PH 12017501248 A1 PH12017501248 A1 PH 12017501248A1 PH 12017501248 A PH12017501248 A PH 12017501248A PH 12017501248 A PH12017501248 A PH 12017501248A PH 12017501248 A1 PH12017501248 A1 PH 12017501248A1
Authority
PH
Philippines
Prior art keywords
oxazino
benzotriazine
dione
fluorophenyl
cyclopropyl
Prior art date
Application number
PH12017501248A
Inventor
Sylvie Bretin
Laurence Danober
Pierre Lestage
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of PH12017501248A1 publication Critical patent/PH12017501248A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

The invention relates to a combination of 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3H-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione, of the following formula [I], or one of the acid addition salts or pharmaceutically acceptable base addition salts thereof, with an antidepressant. The invention is of use in drugs.
PH12017501248A 2015-03-26 2017-07-06 New association between 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione and an antidepresant and pharmaceutical compositions containing it PH12017501248A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1552563A FR3034019B1 (en) 2015-03-26 2015-03-26 NOVEL ASSOCIATION BETWEEN 8-CYCLOPROPYL-3- [2- (3-FLUOROPHENYL) ETHYL] -7,8-DIHYDRO-3H- [1,3] OXAZINO [6,5-G] [1,2,3] BENZOTRIAZINE -4,9-DIONE AND AN ANTIDEPRESSANT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
PCT/FR2016/050681 WO2016151265A1 (en) 2015-03-26 2016-03-25 Novel combination of 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione with an antidepressant, and the pharmaceutical compositions containing same

Publications (1)

Publication Number Publication Date
PH12017501248A1 true PH12017501248A1 (en) 2017-10-30

Family

ID=53776719

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12017501248A PH12017501248A1 (en) 2015-03-26 2017-07-06 New association between 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione and an antidepresant and pharmaceutical compositions containing it

Country Status (12)

Country Link
EP (1) EP3273996A1 (en)
JP (1) JP2018509436A (en)
KR (1) KR20170125835A (en)
AU (1) AU2016238625A1 (en)
CA (1) CA2975571A1 (en)
FR (1) FR3034019B1 (en)
MA (1) MA41817A (en)
PH (1) PH12017501248A1 (en)
SG (1) SG11201706076QA (en)
TN (1) TN2017000280A1 (en)
WO (1) WO2016151265A1 (en)
ZA (1) ZA201705052B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG163545A1 (en) * 2007-01-03 2010-08-30 Servier Lab 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses

Also Published As

Publication number Publication date
FR3034019B1 (en) 2017-03-17
CA2975571A1 (en) 2016-09-29
FR3034019A1 (en) 2016-09-30
EP3273996A1 (en) 2018-01-31
TN2017000280A1 (en) 2019-01-16
SG11201706076QA (en) 2017-08-30
ZA201705052B (en) 2019-02-27
AU2016238625A1 (en) 2017-08-03
MA41817A (en) 2018-01-30
KR20170125835A (en) 2017-11-15
WO2016151265A1 (en) 2016-09-29
JP2018509436A (en) 2018-04-05

Similar Documents

Publication Publication Date Title
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
MX2018011831A (en) SOLUBLE C5aR ANTAGONISTS.
PH12018500904A1 (en) Peptide macrocycles against acinetobacter baumannii
PH12016502081A1 (en) Compounds for treating spinal muscular atrophy
MX2021006804A (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders.
EA201891099A1 (en) 7- (TIAZOL-5-IL) Pyrrolopyrimide as an agonist of the TLR7 receptor
MX2018005890A (en) Compositions for treating spinal muscular atrophy.
MD20170016A2 (en) Aminopyrimidinyl compounds as JAK inhibitors
PH12018500061A1 (en) Oxysterols and methods of use thereof
MX2020011449A (en) Oxysterols and methods of use thereof.
NZ735575A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
MX2019002180A (en) Muscarinic m1 receptor positive allosteric modulators.
PH12018500378B1 (en) Novel annelated phenoxyacetamides
PH12018500377A1 (en) Novel annelated benzamides
TW201613864A (en) Novel compounds
MX2017011978A (en) Deuterated analogs of etifoxine, their derivatives and uses therof.
EP3162804A8 (en) New benzodiazepine derivative and use thereof
TR201819805T4 (en) FLAVAGLIN DERIVATIVES.
MX2017002544A (en) Isoquinolinone derivatives useful in the treatment of cancer.
PH12017501248A1 (en) New association between 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione and an antidepresant and pharmaceutical compositions containing it
WO2015181837A3 (en) Novel compounds as anti-tubercular agents
MX2020009711A (en) Combination of quinoline-4-carboxamides and benzonaphthyridine derivatives as antimalarial drug combination.
PH12016501982A1 (en) NEW ASSOCIATION BETWEEN 8-CYCLOPROPYL-3-[2-(3-FLUOROPHENYL)ETHYL]-7,8-DIHYDRO-3H-[1,3]OXAZINO[6,5-g][1,2,3]BENZOTRIAZINE-4,9-DIONE AND AN ACETYLCHOLINESTERASE INHIBITOR, AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
EA201600360A3 (en) PHARMACEUTICAL COMPOSITIONS BASED ON 9-BUTYLAMINO-3,3-DIMETHYL-3,4-DIHYDROACRIDINE-1 (2H) -ON HYDROCHLORIDE FOR CORRECTION OF COGNITIVE AND NEUROLOGICAL DISORDERS
MX2017008497A (en) Novel heterocyclic compounds and the use thereof in medicine and in cosmetics.